Comprehensive molecular profiling of pretreatment metastatic castration resistant prostate cancer (CRPC): Secondary data from NCI 9012, a randomized ETS fusion-stratified phase II trial.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 IDEAL trial results for Livdelzi in primary biliary cholangitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results